Filing Details
- Accession Number:
- 0001638599-20-000977
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-17 16:06:16
- Reporting Period:
- 2020-12-15
- Accepted Time:
- 2020-12-17 16:06:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1535955 | Lipocine Inc. | LPCN | Pharmaceutical Preparations (2834) | 990370688 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1579872 | V. Mahesh Patel | 675 Arapeen Drive Suite 202 Salt Lake City UT 84010 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-16 | 45,000 | $0.00 | 1,243,090 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-12-16 | 15,000 | $1.35 | 1,228,090 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2020-12-15 | 375,000 | $1.37 | 375,000 | $1.37 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2020-12-16 | 45,000 | $0.00 | 45,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 375,000 | 2021-12-15 | 2030-12-15 | No | 4 | A | Direct |
| 45,000 | 2020-12-16 | 2027-01-25 | No | 4 | M | Direct |
Footnotes
- Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
- Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.
- Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Billionaire Hedge Funds
